BREAKING: Target Test Prep releases Brand New 2026 On Demand GMAT prep course

Redeem

Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

★★★★★5.0559 reviews
Vote for Target Test Prep, Newsweek Readers’ Choice Awards 2026
NEWSWEEK READERS’ CHOICE 2026

BIG NEWS! Target Test Prep has been nominated, and they’d love your vote!

TTP has worked incredibly hard to build the best test prep experience possible, and winning Newsweek’s 2026 Readers’ Choice Award for Best Test Prep would mean a lot to them. If TTP has helped you, they’d be incredibly grateful for your vote. You can vote once each day through September 9.

Vote for TTP
GMATLiveTeach 7 seats left
Chris Peckover
NEXT LIVE COHORT

Oct 13 to Jan 7, 2027

with Chris Peckover

Schedule
Tue, Thu · 8:00 to 10:00 PM ET
Included
40 live hours + 6 months of GMAT OnDemand
  • Live instruction and real-time questions
  • Class recordings and assigned practice
View class & enroll
Limited cohort · enrollment openTarget Test Prep
EALiveTeach 5 seats left
Logan Thompson
EXECUTIVE ASSESSMENT

Sep 6 to Dec 6, 2026

with Logan Thompson

Schedule
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll
Limited cohort · enrollment openTarget Test Prep
GMATOnDemand Start anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Compare the format, schedule, and included access before enrolling. Prices and seat counts shown reflect the supplied offer details.

A new drug, taken twice daily for one month

Expert replies
by NandishSS » Wed Dec 14, 2016 11:13 pm
A new drug, taken twice daily for one month, is an effective treatment for a certain disease. The drug now most commonly prescribed for the disease occasionally has serious side effects such as seizures; the new drug has side effects much more frequently, but the worst of them is mild nausea. Therefore, the new drug is clearly preferable as a treatment.

Which of the following, if true, most seriously weakens the argument?

A) It is possible that the drug now most commonly prescribed has side effects that have not yet been attributed to it.
B) People who experience nausea are prone to discontinue use of the new drug prematurely.
C) Other drugs for the disease have typically been prescribed only for patients allergic to the most commonly prescribed drug.
D) People who have received effective treatment for disease do not generally contract the disease again.
E) There is a nonprescription medication that when taken with the new drug prevents the onset of nausea.

OA:B

Source:GMATPrep EP2
Join the discussion
Source: — Critical Reasoning |

by ceilidh.erickson » Thu Dec 15, 2016 5:31 pm
Whenever we want to WEAKEN an argument, we must first assess the line of reasoning, and see where it is flawed.

Conclusion:
- the new drug is clearly preferable as a treatment

Premises:
- drug now most commonly prescribed for the disease occasionally has serious side effects such as seizures
- the new drug has side effects much more frequently, but the worst of them is mild nausea

Assumptions:
- the only important criteria in assessing which drug is "preferable" is the severity of side effects
- or, the drugs are equally effective
- frequent but mild side effects are preferable to infrequent but severe ones

In order to WEAKEN the argument, we must find an answer choice that attacks one of these assumptions.

A) It is possible that the drug now most commonly prescribed has side effects that have not yet been attributed to it.
This would strengthen rather than weaken; it gives us more reason to believe that the new drug is preferable.

B) People who experience nausea are prone to discontinue use of the new drug prematurely.
If this is true, then people will stop taking the new drug, limiting its effectiveness. This gives us reason to doubt whether this drug will be preferable. Correct.

C) Other drugs for the disease have typically been prescribed only for patients allergic to the most commonly prescribed drug.
Irrelevant. The conclusion is only concerned with the comparison between these two drugs, so we don't care about other (presumably less preferable) drugs.

D) People who have received effective treatment for disease do not generally contract the disease again.
Irrelevant to this argument. It gives us no reason to conclude that one drug is preferable to the other, as both are presumed effective.

E) There is a nonprescription medication that when taken with the new drug prevents the onset of nausea.

This would strengthen rather than weaken. The new drug's worst side effect is easily prevented, giving us more reason to prefer it. We need an answer that says the opposite.

The answer is B.
Ceilidh Erickson
EdM in Mind, Brain, and Education
Harvard Graduate School of Education
Join the discussion

by meenakshimiyer » Sat Jan 12, 2019 9:02 pm
Nausea is the weakening point for the new drug while the drug used now has many serious weakening points. If we have to weaken the preference of new drug over old drug, we have to consider people who experience nausea and show that they won't prefer the new drug. Choice B does the required. Hence, B is the answer.
Join the discussion